Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in Europe
Year: 2026
Type: article
Abstract: Not available.
Source: Haematologica
Authors: Michele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, Michel Delforge, Fernando Escalante, David Kleinman, Hans C. Lee, Ravi Vij, Richard Greil, Thomas Melchardt, Elisabetta Antonioli, Anna Lysen, Leena Camadoo-O’Byrne, Jacopo Bitetti, Tim D’Estrube, Mark Fry, Julie Byrne, Carla Y. Vossen, Sandhya Sapra, Victoria S. Benson, Jorge Mouro, Malin Hultcrantz
Institutions: University of Bologna, Oslo University Hospital, Korea University, National and Kapodistrian University of Athens, KU Leuven, Hospital Universitario de León, University of Rochester Medicine, The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, Paracelsus Medical University, Azienda Ospedaliero-Universitaria Careggi, GlaxoSmithKline (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W7125382268
FWCI:
Cites:
Cited by:
Related to: